| Autor: |
Montoya-Estrada A; Coordination of Gynecological and Perinatal Endocrinology, National Institute of Perinatology, Ministry of Health, Mexico City, México., Veruete-Bedolla DB; Coordination of Gynecological and Perinatal Endocrinology, National Institute of Perinatology, Ministry of Health, Mexico City, México., Romo-Yañez J; Coordination of Gynecological and Perinatal Endocrinology, National Institute of Perinatology, Ministry of Health, Mexico City, México., Ortiz-Luna GF; Peri and Postmenopause Clinic, National Institute of Perinatology, Ministry of Health, Mexico City, México., Arellano-Eguiluz A; Peri and Postmenopause Clinic, National Institute of Perinatology, Ministry of Health, Mexico City, México., Najéra N; Postgraduate and Research Section, Higher School of Medicine, National Polytechnic Institute, Mexico City, México., Ceballos G; Postgraduate and Research Section, Higher School of Medicine, National Polytechnic Institute, Mexico City, México., Nieto-Velázquez NG; Research Division, Hospital Juárez de México, Ministry of Health, Mexico City, Mexico., Ramos-Valencia MA; Central Laboratory, National Institute of Perinatology, Ministry of Health, Mexico City, México., Cariño-Mancilla N; Central Laboratory, National Institute of Perinatology, Ministry of Health, Mexico City, México., Valdez-Rodríguez NL; Central Laboratory, National Institute of Perinatology, Ministry of Health, Mexico City, México., Flores-Pliego A; Department of Immunobiochemistry, National Institute of Perinatology, Ministry of Health, México City, Mexico., Espejel-Nuñez A; Department of Immunobiochemistry, National Institute of Perinatology, Ministry of Health, México City, Mexico., Reyes-Muñoz E; Coordination of Gynecological and Perinatal Endocrinology, National Institute of Perinatology, Ministry of Health, Mexico City, México. |
| Abstrakt: |
During the postmenopausal period, there are metabolic alterations that predispose individuals to metabolic syndrome (MS), oxidative stress (OS), and the risk of developing cardiovascular diseases. We aimed to compare the concentrations of OS markers in postmenopausal women with and without MS. Malondialdehyde, carbonyl groups, and total antioxidant capacity (TAC) were quantified. We conducted a cross-sectional study: Group 1 (n = 42) included women without MS, and Group 2 (n = 58) comprised women with MS. Participants' age was similar between groups. Glucose, insulin, the homeostasis model assessment of insulin resistance, triglycerides, uric acid, and body mass index were significantly lower in postmenopausal women without MS. OS markers were significantly lower in Group 1 vs. Group 2: malondialdehyde, 31.32 ± 14.93 vs. 40.27 ± 17.62 pmol MDA/mg dry weight ( p = .01); protein carbonylation, 6325 ± 1551 vs. 7163 ± 1029 pmol PC/mg protein ( p = .0003); and TAC, 1497 ± 297.3 vs. 1619 ± 278.8 pmol Trolox equivalent/mg protein ( p = .041). OS markers were significantly higher in postmenopausal women with MS. Impact statement What is already known on this subject? Oxidative stress has been implicated in numerous disease processes; however, information on the relationship between oxidative stress and metabolic syndrome among postmenopausal women remains limited. What do the results of this study add? Our results indicate that in postmenopausal Mexican women, oxidative stress markers were significantly lower in those without metabolic syndrome, whereas total antioxidant capacity was higher in those with metabolic syndrome, which could be explained as an antioxidant defense mechanism capable of neutralising excess oxidative damage markers. What are the implications of these findings for clinical practice and/or further research? This study is of interest to a broad audience because it compares the concentrations of oxidative stress markers in postmenopausal women with and without metabolic syndrome. Our study could support intervention with supplements or foods rich in antioxidants as lifestyle modifications in postmenopausal women with metabolic syndrome. |
